11 August 2022 · Bupivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Levobupivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Vancomycin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Amikacin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
12 July 2022 · CAR-T Therapy requires some medicines to be restricted, this guidance provides details and recommended wash-out periods for restricted medicines.
12 July 2022 · This document provides expert clinical pharmacy guidance on supportive medicines in order to facilitate the treatment of complex CAR-T Cell Therapy patients.
29 June 2022 · Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team